InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Scherle Peggy, Directeur Scientifique. Director active across 1 company, notably Prelude Therapeutics Inc. Cumulatively, 4 disclosures have been published. History available since 7 May 2021. The latest transaction was disclosed on 26 August 2021 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Scherle Peggy
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
1,700 shares@ US$1.435.3% of flowCommon StockSEC:0001209191-21-053867:0
558 shares@ US$1.892.3% of flowCommon StockSEC:0001209191-21-051885:0
20,000 shares@ US$1.4362.0% of flowCommon StockSEC:0001209191-21-048688:0
10,000 shares@ US$1.4330.4% of flowCommon StockSEC:0001209191-21-031847:0
4 of 4 declarations
About Scherle Peggy
Peggy Scherle is the Chief Scientific Officer at Prelude Therapeutics Inc, a biopharmaceutical company. She is responsible for leading research and development initiatives aimed at innovating in the field of medical treatments.
